BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Moradi A, Sepah YJ, Sadiq MA, Nasir H, Kherani S, Sophie R, Do DV, Nguyen QD. Vascular endothelial growth factor trap-eye (Aflibercept) for the management of diabetic macular edema. World J Diabetes 2013; 4(6): 303-309 [PMID: 24379921 DOI: 10.4239/wjd.v4.i6.303]
URL: https://www.wjgnet.com/1948-9358/full/v4/i6/303.htm
Number Citing Articles
1
Deep Shikha Sharma, Sheetu Wadhwa, Monica Gulati, Arya Kadukkattil Ramanunny, Ankit Awasthi, Sachin Kumar Singh, Rubiya Khursheed, Leander Corrie, Nitin Chitranshi, Vivek Kumar Gupta, Sukriti Vishwas. Recent advances in intraocular and novel drug delivery systems for the treatment of diabetic retinopathyExpert Opinion on Drug Delivery 2021; 18(5): 553 doi: 10.1080/17425247.2021.1846518
2
E Al Kahtani, Z Xu, S Al Rashaed, L Wu, A Mahale, J Tian, E B Abboud, N G Ghazi, I Kozak, V Gupta, J F Arevalo, E J Duh. Vitreous levels of placental growth factor correlate with activity of proliferative diabetic retinopathy and are not influenced by bevacizumab treatmentEye 2017; 31(4): 529 doi: 10.1038/eye.2016.246
3
Fatma Savur, Havva Kaldırım, Kürşat Atalay, Tülin Öğreden, Şerife Çiloğlu Hayat. Treatment results of diabetic macular edema with different choroidal thickness with intravitreal anti vascular endothelial growth factorBMC Ophthalmology 2022; 22(1) doi: 10.1186/s12886-022-02721-3
4
Otzem Chassid, Karine Beiruti Wiegler, Ala Bashir, Dan Arad, Gilad Hadar, Adi Sharabi-Nov, Yuval Cohen. Effectiveness of aflibercept, ranibizumab, and Ozurdex for treating diabetic macular edema showing a suboptimal response: A comparative observational studyTaiwan Journal of Ophthalmology 2025;  doi: 10.4103/tjo.TJO-D-24-00122
5
Joana F. Fangueiro, Amélia M. Silva, Maria L. Garcia, Eliana B. Souto. Current nanotechnology approaches for the treatment and management of diabetic retinopathyEuropean Journal of Pharmaceutics and Biopharmaceutics 2015; 95: 307 doi: 10.1016/j.ejpb.2014.12.023
6
Işıl Kutlutürk Karagöz, Adil Allahverdiyev, Melehat Bağırova, Emrah Şefik Abamor, Sahar Dinparvar. Current Approaches in Treatment of Diabetic Retinopathy and Future PerspectivesJournal of Ocular Pharmacology and Therapeutics 2020; 36(7): 487 doi: 10.1089/jop.2019.0137
7
Imène Zhioua, Oudy Semoun, Franck Lalloum, Eric H. Souied. INTRAVITREAL DEXAMETHASONE IMPLANT IN PATIENTS WITH RANIBIZUMAB PERSISTENT DIABETIC MACULAR EDEMARetina 2015; 35(7): 1429 doi: 10.1097/IAE.0000000000000490
8
Kuan Hao Yee, Srinivasan Sanjay. Anti-Vascular Endothelial Growth Factor Therapy in Diabetic Macular Oedema: Is It Effective?EMJ Diabetes 2017; : 118 doi: 10.33590/emjdiabet/10313316
9
Jean-Francois Korobelnik, Jos Kleijnen, Shona H Lang, Richard Birnie, Regina M Leadley, Kate Misso, Gill Worthy, Dominic Muston, Diana V Do. Systematic review and mixed treatment comparison of intravitreal aflibercept with other therapies for diabetic macular edema (DME)BMC Ophthalmology 2015; 15(1) doi: 10.1186/s12886-015-0035-x
10
Sanket U. Shah, Raj K. Maturi. Therapeutic Options in Refractory Diabetic Macular OedemaDrugs 2017; 77(5): 481 doi: 10.1007/s40265-017-0704-6
11
Shigeo Yoshida, Tomoaki Murakami, Miho Nozaki, Kiyoshi Suzuma, Takayuki Baba, Takao Hirano, Osamu Sawada, Masahiko Sugimoto, Yoshihiro Takamura, Eiko Tsuiki. Review of clinical studies and recommendation for a therapeutic flow chart for diabetic macular edemaGraefe's Archive for Clinical and Experimental Ophthalmology 2021; 259(4): 815 doi: 10.1007/s00417-020-04936-w
12
Hanife Rahmanlar, Cemile Üçgül Atılgan, Mehmet Çıtırık, İbrahim Muaz Yaradılmış, Hakkı Gürsöz. Türkiye’de Diyabetik Retinopati Tanısında Endikasyon Dışı İlaç KullanımıSakarya Medical Journal 2019; 9(3): 499 doi: 10.31832/smj.543998
13
Irini Chatziralli, Anat Loewenstein. Intravitreal Anti-Vascular Endothelial Growth Factor Agents for the Treatment of Diabetic Retinopathy: A Review of the LiteraturePharmaceutics 2021; 13(8): 1137 doi: 10.3390/pharmaceutics13081137
14
Blessing C. Ilochonwu, Arto Urtti, Wim E. Hennink, Tina Vermonden. Intravitreal hydrogels for sustained release of therapeutic proteinsJournal of Controlled Release 2020; 326: 419 doi: 10.1016/j.jconrel.2020.07.031
15
Haiyan Chen, Xuehui Shi, Wang Zhang, Qianqian Han. Aflibercept versus ranibizumab for diabetic macular edema: A meta-analysisEuropean Journal of Ophthalmology 2024; 34(3): 615 doi: 10.1177/11206721231178658
16
Farheen Tariq, Yanfen Wang, Bo Ma, Yidan He, Shu Zhang, Ling Bai. Efficacy of Intravitreal Injection of Filtered Modified Low-Dose Triamcinolone Acetonide and Ranibizumab on Pseudophakic Cystoid Macular EdemaFrontiers in Medicine 2022; 9 doi: 10.3389/fmed.2022.777549
17
Dong Wook Kang, Seok-jin Cho, Go-Wun Choi, Ju Hee Kim, Hea-Young Cho. Physiologically-based pharmacokinetic modeling of enavogliflozin ophthalmic solution for starting dose selection in diabetic retinopathy treatmentBiomedicine & Pharmacotherapy 2025; 193: 118722 doi: 10.1016/j.biopha.2025.118722
18
Douglas A. MacDonald, Joel Martin, Kathir K. Muthusamy, Jiann-Kae Luo, Erica Pyles, Ashique Rafique, Tammy Huang, Terra Potocky, Yang Liu, Jingtai Cao, Françoise Bono, Nathalie Delesque, Pierre Savi, John Francis, Ali Amirkhosravi, Todd Meyer, Carmelo Romano, Meredith Glinka, George D. Yancopoulos, Neil Stahl, Stanley J. Wiegand, Nicholas Papadopoulos. Aflibercept exhibits VEGF binding stoichiometry distinct from bevacizumab and does not support formation of immune-like complexesAngiogenesis 2016; 19(3): 389 doi: 10.1007/s10456-016-9515-8
19
Walid S. Ibrahim, Zeiad H. Eldaly, Mohamed G. Saleh, Mahmoud F. Rateb, Ahmed H. Aldoghaimy. Switching to Aflibercept in Diabetic Macular Edema after Unsatisfactory Response to Other Anti-vascular Endothelial Growth Factor DrugsKorean Journal of Ophthalmology 2019; 33(2): 122 doi: 10.3341/kjo.2018.0037
20
Lyndell L Lim, Julie L Morrison, Marios Constantinou, Sophie Rogers, Sukhpal S Sandhu, Sanjeewa S Wickremasinghe, Ryo Kawasaki, Salmaan Al‐Qureshi. Diabetic Macular Edema at the time of Cataract Surgery trial: a prospective, randomized clinical trial of intravitreous bevacizumab versus triamcinolone in patients with diabetic macular oedema at the time of cataract surgery – preliminary 6 month resultsClinical & Experimental Ophthalmology 2016; 44(4): 233 doi: 10.1111/ceo.12720
21
Eda I. Altiok, Shane Browne, Emily Khuc, Elizabeth P. Moran, Fangfang Qiu, Kelu Zhou, Jorge L. Santiago-Ortiz, Jian-xing Ma, Matilda F. Chan, Kevin E. Healy, Guei-Sheung Liu. sFlt Multivalent Conjugates Inhibit Angiogenesis and Improve Half-Life In VivoPLOS ONE 2016; 11(6): e0155990 doi: 10.1371/journal.pone.0155990
22
Havva Kaldırım, Serpil Yazgan, Ahmet Kırgız, Kursat Atalay, Fatma Savur. A Comparison Study of Ranibizumab and Aflibercept in Patients with Naive Diabetic Macular Edema in Presence of Serous Retinal DetachmentCurrent Eye Research 2019; 44(9): 987 doi: 10.1080/02713683.2019.1608260
23
Dante Akira Kondo Kuroiwa, Fernando Korn Malerbi, Caio Vinicius Saito Regatieri. New Insights in Resistant Diabetic Macular EdemaOphthalmologica 2021; 244(6): 485 doi: 10.1159/000516614
24
Shahin Faghihi, Hooshang Faghihi, Mir Alborz Faiez, Abbas Mohammadi, Esmaeil Asadi Khameneh, Elias Khalili Pour, Hamid Riazi-Esfahani. Persistent Diabetic Macular Edema: A Comprehensive Review of Current Treatments and Emerging Therapeutic OptionsJournal of Current Ophthalmology 2024; 36(3): 229 doi: 10.4103/joco.joco_133_24
25
Giannis-Aimant Moustafa, Marilita M Moschos. Intravitreal aflibercept (Eylea) injection for cystoid macular edema secondary to retinitis pigmentosa - a first case report and short review of the literatureBMC Ophthalmology 2015; 15(1) doi: 10.1186/s12886-015-0033-z